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Previous dosimetric breath-hold technique studies focused on 
anticipated cardiopulmonary toxicity. In this study we compared 
inspiration gating (IG) with free breathing techniques focusing on breast 
coverage. 
 
Materials and Methods: 49 consecutive patients with left sided BC were 
included in this study. All of the patients underwent lumpectomy and 
then treated with adjuvant radiation using the RPM system, at the Sheba 
Medical Center, during 2009-2012. 
Two CT simulations were generated for each patient prior to treatment: 
the first during free breathing (FB) and the other during RPM IG. Planning 
target volume (PTV) and clinical target volume (CTV) were defined as 
the whole left breast and the tumor excision area, respectively (using 
RTOG definition). An optimized treatment plan was created for each 
scan, and a dosimetric comparison regarding breast (PTV and CTV) 
coverage as well as heart and lungs doses, was carried out. 
 
Results: PTV V95% and Dmean were higher with IG vs. FB (82.38% vs. 
78.88%, P=0.002, 95.73% vs. 93.63%, p<0.001,respectively). CTV V95% 
and Dmean were also higher with IG (98.87% vs. 88.92%, p=0.001, 99.14% 
vs. 96.73%, p=0.003, respectively). PTV V105% and maximum dose were 
not statistically different. The cardiac dose was lower with IG vs. FB 
(heart Dmean was 2.36Gy vs. 2.91Gy, P<0.001; heart V2% was 14.62% 
vs.17.59%, p<0.001). The IG left lung dose was higher (13.28Gy vs. 
12.10Gy, p=0.027). No statistical difference was found for left lung V20. 
 
Conclusions: In patients with suboptimal treatment plan due to anterior 
heart position on free breathing treatment plan, IG using the RPM system 
enabled better breast coverage, excellent CTV Dmean and reduced 
cardiac doses with no difference in lung V20. 
These left sided breast cancer patients with anterior heart position are 
now routinely treated using the RPM system in our institution. 
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Purpose/Objective: Randomized clinical trials (RCT) have demonstrated 
equivalent survival for breast-conserving therapy with radiation (BCT)and 
mastectomy for early-stage breast cancer. Early stage breast cancer 
patients who underwent BCT or mastectomy was studied to observe 
whether outcomes of RCT were achieved in a single institution series, 
and whether survival differed by surgery type when stratified by age and 
hormone receptor (HR) status.  
 
Materials and Methods: Information was obtained from the institutional 
breast cancer data base with stage I or II breast cancer between 1990 
and 2007, who were treated with either BCT or mastectomy and 
followed for vital status through December 2012. Cox proportional 
hazards modeling was used to compare overall survival (OS) and disease-
specific survival (DSS) between BCT and mastectomy groups. Analyses 
were stratified by age group (<= 40 years and >40 years) and tumor HR 
status.  
 
Results: A total of 2525 women fulfilled eligibility criteria. Women 
undergoing BCT had improved OS and DSS compared with women with 
mastectomy (adjusted hazard ratio for OS =0.6, 95% CI =0.4-0.8, 
p=0.0023; adjusted hazard ratio for DSS =0.6, 95%CI =0.4-0.8, p=0.0028). 
The group achieving greatest benefit in DSS with BCT relative to 
mastectomy were women aged 40 or younger at diagnosis with HR-
positive tumors (hazard ratio =0.3, 95% CI =0.1-0.7, p=0.007); however, 





Conclusions: Among patients with early stage breast cancer, BCT was 
associated with improved DSS and OS. These data provide confidence 
that BCT remains an effective alternative to mastectomy for early stage 
disease regardless of age or HR status. 
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Purpose/Objective: 1) To evaluate if there is a reduction in OAR doses 
when using deep inspiration breath-hold for left-sided breast 
radiotherapy. In particular,is there a reduction in cardiac dose which can 
lead to long term radiation induced cardiac toxicity. 
2) Determine if traditional field markup approaches need to be adapted, 
in particular limiting fields to maximum central lung depths (CLD).  
 
Materials and Methods: At our centres all Breast patients are CT 
planned and the lungs and heart are contoured on the CT dataset to 
allow us to analyse dose statistics volumetrically. For left breast patients 
where Deep Inspiration Breath Hold (DIBH) is deemed beneficial two CTs 
are acquired in the initial planning session, the initial scan is free 
breathing and the second is acquired during DIBH. Fields are placed on 
the DIBH CT and then, based on tissue volume equivalence, copied to the 
free breathing scan. Clinically optimum plans are completed on both 
data sets and the dose statistics analysed for comparison. 
 
Results: Data from 30 patients who were treated with DIBH and Forward-
Planned IMRT were analysed to determine the dose vs. volumetric 
effecton the lung and heart. In all cases the heart dose is drastically 
reduced with DIBH almost eradicating dose completely. Previously we 
carried out analyses of central lung depth vs. lung volume which clearly 
showed that there is no correlation between distance measured and 
volume treated. In all cases, the use of DIBH did demonstrate an 
increase in average CLD, however there was also no correlation between 
CLD and lung volume, in line with the previous study. 
 
Conclusions: DIBH is beneficial for left sided breast treatments. 
Particular benefit is seen by reducing the heart dose as research suggests 
irradiating the heart can be detrimental in relation to long term 
radiation related cardiovascular side-effects. 
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Purpose/Objective: To present the first clinical results of prone breast 
RT using Sagittilt© (Orfit Industries, Wijnegem, Belgium) system in terms 
of patient comfort, RTT satisfaction, set-up accuracy, intrafractional 
movement and acute toxicity.  
 
Materials and Methods: Twenty patients (17 right sided/3 left sided 
breast cancers) underwent whole breast irradiation in prone position. 
The first 17 patients were treated with sequential boost (breast: 42.56 
Gy/16 fractions, boost: 10 Gy/5 fractions). Three patients were treated 
with concomitant boost protocol (breast/boost: 45.57/55.86 Gy in 21 
fractions). Tilting function was used in 4/20 patients. Treatment 
verification included a daily online corrected cone-beam CT (CBCT). 
Furthermore in order to evaluate stability of the patient position, post-
treatment CBCT were performed systematically at the first 5 treatment 
sessions. Treatment time, patient comfort and RTT satisfaction scores 
were also evaluated. A radar representation was used to determine 
points where most improvements could be made.  
 
Results: The pre-treatment CBCT resulted in a population systematic 
error of 2.9/3.5/2.8 mm for lateral/longitudinal/vertical direction 
(LA/LO/VE), while for the random error 2.0/1.0/0.8 mm. Without 
correction these would correspond to a margin of 6.3/8.1/5.1 mm. The 
average time between the two CBCTs was just above 8 minutes. The 
post-treatment residual error was an average of 1.5/1.3/1.9 mm and was 
considered good. The patient and RTT oriented comfort questionnaire’s 
average score was 4.3 and 3.1,thus excellent and average/good. Figure 1 
represents the patient comfort during the entire treatment. Acute 
toxicity (G0/G1/G2/G3+)was the followings: Dermatitis: 1/11/8/-, 





Figure 1. Radar representation of patient comfort questionnaire. 
 
Conclusions: The Sagittilt© system seems to be a well-designed prone 
breast board as the early clinical results show good patient comfort, 
small setup and residual errors,and low acute toxicity. Further 
improvements (e.g. improve RTT satisfaction,higher setup accuracy) and 
larger cohort of patients are needed for reassuring the early clinical 
findings. 
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Purpose/Objective: Management of loco-regional recurrences (LRR) in 
previously irradiated and treated breast cancers is a therapeutic 
challenge. Hyperthermia (HT) at 41-43°C, with its radiosensitizing 
properties and inherent thermal cytotoxic capabilities is explored 
currently with re-irradiation (ReRT) for this condition. Our study is a 
retrospective evaluation of local thermo-radiotherapy in the 
management of LRR in previously irradiated breast cancer. The primary 
endpoint assessed is local control following ReRT and HT. 
 
Materials and Methods: Between 2006 and 2013, 38 previously treated 
breast cancer patients, with various combinations of surgery, local 
radiotherapy (RT),chemotherapy and/or hormones and who later 
developed LRR in the ipsilateral chest wall (n= 16), regional lymph nodes 
(n=4) or both (n=4) were considered for ReRT with HT at our institution. 
All patients had received previous RT to the loco-regional site. They 
were treated with 915 Mhz microwaves for 60 minutes to 41-43°C, once 
or twice a week using BSD 500 system. Real time thermometry for the 
local site was carried out using multiple thermal sensors during the 
entire HT sessions. Depending on the site, size, dose and time of 
previous RT, a dose of 20 – 50Gy (mean + SD: 36.8 + 8.5Gy) was delivered 
at a dose/fr. of 1.8–4.0 Gy (mean + SD: 2.33 + 0.56Gy). Re-RT was 
carried out within 1 hour before or following HT sessions. Treatment 
outcomes were assessed by follow up consultations, phone calls or 
individual patient's follow-up records. 
 
Results: Of the 38 patients, 14 were considered as non-evaluable as 
their follow-up details were not adequate to assess the treatment 
outcome. Thus, 24 patients were finally evaluable. They had an interval 
of 0–22 years (median : 6 years) between their first treatment and 
referral for treatment of LRR. The mean BED (Gy10) of Re-RT was 45.25 
Gy10 (SD: +9.8) (range:28 – 60 Gy10). Patients received 2 sessions of HT 
per week and a total of 2 to 11 HT sessions (mean + SD: 7.3 + 2.3) were 
applied along with Re-RT. An objective response of 91.7% (22/24) was 
observed of which 66.7% (16/24) had a complete response (CR) and 25% 
(6/24), a partial response. All the 16 patients who had achieved a CR 
following ReRT and HT, maintained their CR status till the end of follow-
up or death (median: 10 months, range: 2 to 32 months). HT was well 
tolerated and 41.7% and 58.3% of the patients experienced only grade I 
or II skin reactions respectively which recovered on conservative 
management within 3 to 4 weeks of completion of treatment. There was 
no evidence of any late toxicity. 
 
Conclusions: Local HT with ReRT is an effective modality to treat LRR in 
previously irradiated breast cancers. The complete responses achieved 
with ReRT and HT is sustainable during post-treatment follow up period. 
Local thermo-radiotherapy can thus, be safely delivered, well tolerated 
and produces long term effective palliation in LRR with minimal 
morbidity. 
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Purpose/Objective: To report a phase II study protocol and early clinical 
experience, analysis of the dosimetric parameters, determination of 
setting inaccuracy of accelerated partial breast irradiation (APBI) with 
image-guided (IG-) intensity modulated radiotherapy (IMRT) following 
breast-conserving surgery (BCS) for early-stage breast cancer.  
 
Materials and Methods: Between 2011 and 2013, in 51 cases of low-risk, 
pT1-2 (≤30 mm) pN0 M0 breast cancer, post operative APBI was given by 
means of IG-IMRT using static MLC („step-and-shoot') technique with 
kVCT guidance for each fractions. The total dose of APBI was 36.9 Gy (9 
x 4.1 Gy) using twice-a-day fractionation for 5 consecutive days. 
 
Results: The median age was 62 years. Mean tumor size was 11.9 mm. At 
a median follow-up of 12 months neither loco-regional nor distant failure 
was observed. Median GTV(e.g. volume of surgical cavity) was 14.5 cc, 
median CTV was 79.9 cc, and median PTV and PTVeval were 150.8 cc 
and 129 cc. The dose-volume constraints, (V95PTV_EVAL= 100%, 
Dmin(PTVEVAL)≥ 95%, Dmax(PTVEVAL)≤ 110%, ipsilateral breast V100breast ≤ 
35%, V50breast ≤60%, ipsilateral lung V30pulm≤ 20%, V15heart_r ≤ 10%, V5heart_l≤ 
V5heart_tang)) were met in all the treated patients. The median PTV/whole 
breast volume(WB) ratio was 0.16. The average standard deviations of 
setup inaccuracies were 1.4 mm, 1.6 mm, 1.5 mm, and the CTV-PTV 
margins were 5 mm, 6 mm, 6 mm in LAT, LONG, and VERT directions, 
respectively. The incidence of G1 and G2 skin toxicities were 29% and 
4%, respectively. G1 edema was observed in 31%, G1 and G2 pain were 
reported by the patient in 8% and 4%. Grade 3 or worse acute side-effect 
was not observed. The 1 year cosmetic outcome was excellent in 62% 
and good in 38% of the patients. 
 
Conclusions: IG-IMRT is a feasible technique for the delivery of APBI 
following conservative surgery for the treatment of low-risk, early-stage 
invasive breast carcinoma. Image-guide radiotherapy can improve daily 
reproducibility, allowing smaller treatment margins. Early results are 
promising, early radiation side effects are rare or mild, and cosmetic 
results are excellent.  
   
 
 
 
 
 
